PONTE VEDRA, Fla. (Azat TV) – Medical technology firm Treace Medical Concepts, Inc. reported its third-quarter financial results for the period ended September 30, 2026, on November 6, 2026, revealing a strategic pivot toward procedural volume growth alongside a narrowed net loss, Markets Insider reported in a release via GlobeNewswire. The surgical technology manufacturer, specializing in bunion and foot and ankle treatments, faced a slight 4% year-over-year revenue decline but successfully reduced its operating expenses and improved adjusted profitability metrics.
CEO and Chairman John T. Treace pointed to robust clinical adoption and expanding product lines as key drivers behind the performance. The company’s focus on scaling lower-priced, minimally invasive offerings has altered its top-line revenue dynamics while expanding overall market share across foot and ankle surgical procedures.
Revenue Dynamics and Product Mix Shifts
For the third quarter of 2026, Treace recorded total revenue of $48.3 million, marking a 4% decrease compared to $50.2 million during the same period in 2025. According to the Markets Insider disclosure, this top-line contraction was primarily driven by a strategic shift in revenue mix toward lower-priced minimally invasive products and a reduced volume of traditional bunion procedure kits sold.
However, excluding sales to stocking distributors, underlying bunion kit sales volume actually increased, translating into mid-single-digit revenue growth relative to the third quarter of 2025. Executive leadership emphasized that newer product offerings, such as the SuperBite compression screws, are enabling surgeon customers to penetrate a significantly broader range of common foot and ankle procedures.
Gross profit for the quarter stood at $38.4 million, compared to $39.7 million in the third quarter of 2025. Despite the minor drop in absolute gross profit, the company’s gross margin expanded slightly to 79.5%, up from 79.1% a year earlier, illustrating disciplined manufacturing and cost management.
Operating Expense Discipline and Narrowed Net Losses
To counter the revenue contraction, Treace instituted targeted organizational expense reductions. Total operating expenses for the quarter dropped by $5.5 million, or 10%, falling to $49.9 million from $55.4 million in the third quarter of 2025.
This decisive overhead trimming directly impacted bottom-line results. Treace’s net loss for the third quarter of 2026 narrowed by $3.7 million to $12.6 million, or $0.19 per share, compared to a net loss of $16.3 million, or $0.26 per share, in the comparable period of 2025. Adjusted EBITDA also swung into positive territory, increasing by $2.9 million to $0.3 million, contrasting with an Adjusted EBITDA loss of $2.6 million in the third quarter of 2025.
Furthermore, the company reported substantial progress in liquidity management, cutting year-to-date cash usage by 53% — a reduction of $9.7 million compared to the first nine months of 2025. Treace closed the quarter with $39.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026, alongside an existing credit facility offering up to $115 million in additional borrowing capacity subject to specific conditions.
Updated Guidance and Full-Year Outlook
In light of its year-to-date performance, Treace updated its full-year 2026 financial guidance. The company now expects total annual revenue to range between $206 million and $210 million, a slight adjustment from its previous forecast range of $204 million to $212 million, representing an anticipated annual decline of 3% to 1% compared to full-year 2025.
Concurrently, management improved its Adjusted EBITDA loss projection for the full year 2026, narrowing it to a range of $1.0 million to $2.0 million, compared to the prior expected loss of $3.0 million to $5.0 million. For comparison, Treace reported an Adjusted EBITDA loss of $3.9 million for the full-year 2025. The company reiterated its commitment to reducing annual cash usage by approximately 50% relative to the preceding fiscal year, driven by steady case volume growth and stabilizing year-over-year revenue trajectories.